Market Intelligence, Clinical Progress, and High-Purity Reagents for Clathrin-Mediated Endocytosis and Intracellular Trafficking Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CLTA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLTA Recombinant Protein (Full Length / Truncated) High purity (>95%), Endotoxin controlled. Sequence Verified by LC-MS. |
View CLTA Products |
| Gene Delivery | CLTA Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and endocytosis assays. |
View CLTA Products |
| Benchmark Ab | Anti-CLTA Recombinant Antibody High-affinity positive control for Western Blot, IHC, and IP. |
View CLTA Products |
| Validator | CLTA siRNA Set Target-specific knockdown pool for functional validation of CME pathway. |
View CLTA Products |
| Related Target A | CLTB (Clathrin Light Chain B) Highly homologous light chain; essential for subfamily specificity screening. |
View CLTB Products |
| Related Target B | CLTC (Clathrin Heavy Chain) Core binding partner forming the clathrin triskelion coat. |
View CLTC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CLTA vs. CLTB isoform cross-reactivity | Recombinant CLTA and CLTB proteins strictly verified by mass spectrometry to guarantee isoform specificity. |
| In vitro reconstitution of triskelions | High-purity, monomeric CLTA and CLTC proteins with low aggregation profiles. |
| Lack of reliable positive controls | Sequence-verified biosimilar-grade benchmark antibodies included in the catalog. |
| Off-target phenotype validation | Validated siRNA pools included for parallel knockdown experiments. |
Live CLTA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Clathrin Light Chain A (CLTA) is gaining traction as researchers exploit clathrin-mediated endocytosis (CME) pathways for drug delivery, viral entry inhibition, and oncology. Once regarded strictly as an intracellular structural protein, CLTA is now recognized as a critical regulatory node in receptor tyrosine kinase (RTK) internalization and recycling. The race for CLTA therapeutics is intensifying, with major players shifting focus from traditional mAbs to small-molecule inhibitors of clathrin assembly, protein-protein interaction (PPI) disruptors, and RNA-based therapeutics. As first-generation CME-disrupting molecules reach the clinic, the next wave of R&D is targeting tissue-specific endocytosis inhibition to minimize systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic Consortia, Biotech Startups | Oncology (RTK-driven tumors), Viral Infection | Binding assays (Need high-purity, natively folded CLTA/CLTC complexes) |
| RNA Therapeutics (siRNA/ASO) | Alnylam, Arrowhead, Wave Life Sciences | Neurodegenerative Diseases, Hypercholesterolemia | In vitro knockdown verification (Need validated siRNA and Lentivirus tools) |
| Antibody-Drug Conjugates (ADC Support) | AstraZeneca, Daiichi Sankyo | Solid Tumors (CME kinetic profiling) | Internalization validation (Need stable CLTA-overexpressing reporter cell lines) |